B.Riley Downgrades Ambrx Biopharma (AMAM) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq futures slide as Alphabet results intensify AI spending fears
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Oil falls as diplomacy hopes outweigh Middle East escalation fears
- SK Hynix shares surge after Q3 profit beats expectations
Tweet
Share
E-mailGet Alerts AMAM Hot Sheet
Price: $28.00 --0%
Rating Summary:
4 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 20 | New: 12
Rating Summary:
4 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 20 | New: 12
Join SI Premium – FREE
B.Riley analyst Yuan Zhi downgraded Ambrx Biopharma (NASDAQ: AMAM) from Buy to Neutral with a price target of $28.00 (from $26.00).
For an analyst ratings summary and ratings history on Ambrx Biopharma click here. For more ratings news on Ambrx Biopharma click here.
Shares of Ambrx Biopharma closed at $13.63 yesterday.
You May Also Be Interested In
- BofA Securities Downgrades Fortinet (FTNT) to Neutral
- Northland Starts Digital Turbine (APPS) at Outperform, 'Proven Turnaround'
- Everforth Inc. (EFOR) PT Raised to $38 at Wells Fargo
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
